Allogeneic hemopoietic stem cell transplantation in solid tumors.
The existence of a graft versus tumor (GVT) effect of donor-derived T cells after allogeneic hematopoietic stem cell transplantation is well established as a critical component for the success of the procedure in several hematologic malignancies. Although it has been suggested that a GVT effect might also be generated in patients affected by refractory solid tumors, the morbidity of conventional allogeneic hematopoietic stem cell transplantation has limited its investigation in these diseases. Recently introduced allogeneic nonmyeloablative regimens have greatly decreased morbidity and mortality related to transplants which retain a powerful GVT. On this basis, it has become possible to explore the existence of alloreactivity toward solid tumors. The present article reviews the early clinical results of this novel immunotherapeutic approach for solid tumors.
Carnevale-Schianca
F
F
Medical Oncology, Department of Oncological Sciences, University of Turin Medical School, Institute for Cancer Research and Treatment (I.R.C.C.), Candiolo, Turin, Italy.
Ricchiardi
A
A
Capaldi
A
A
Bucci
A R
AR
Grignani
G
G
Rota-Scalabrini
D
D
Fizzotti
M
M
Aliberti
S
S
Aglietta
M
M
D002292:Carcinoma, Renal Cell / Q000628:therapy; D006086:Graft vs Host Disease; D006801:Humans; D016219:Immunotherapy, Adoptive; D007680:Kidney Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*